Cerulea Clinical Trials

Clinical Trials

Vividwhite

A Prospective Multicentre Pivotal Clinical Study to Demonstrate the Efficacy and Safety of the VividWhite Glaucoma Implant (VW-51) for the Treatment of Glaucoma.

Overview

This Vividwhite study is assessing the effectivness, safety and participant experience of the VW-51(VividFlo) implant for the treatment of glaucoma.

Glaucoma is an eye disease where vision lost due to damage to the optic nerve.

Unfortunately, there is no cure for glaucoma and the vision loss is irreversible.

VW-51 (VividFlo) is intended to be surgically implanted into the subconjunctival space of the eye to drain aqueous humor from the anterior chamber to reduce intraocular pressure (IOP).

As part of the study, suitable participants will be screened to determine their eligibility for the trial.

If eligible, participants will be required to attend our site for at least 10 visits over the duration of one year.

  • Principal Investigator
Dr Jennifer Fan Gaskin

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.